Myelodysplastic Syndrome (MDS) Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Myelodysplastic Syndrome (MDS) Treatment Market is segmented by Treatment Type, End User (Hospitals, Specialty Clinics, and Other End Users), and Geography

Market Snapshot

Myelodysplastic Syndrome (MDS) Treatment Market
Study Period:

2018 - 2026

Base Year:

2020

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

6.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global myelodysplastic syndrome (MDS) treatment market is expected to grow significantly over the forecast period, owing to the increasing pipeline products and product approvals and R&D investments in the development of novel drugs for Myelodysplastic Syndrome (MDS). In 2018, Lupin had received approval for its Decitabine for injection, 50 mg/vial, Single-Dose Vial from the United States Food and Drug Administration (FDA) to market a generic version of Otsuka Pharmaceutical Co. Ltd's Dacogen for Injection, 50 mg/vial, single-dose vial. However, side effects associated with chemotherapy medications might hamper the growth of the market studied.

Scope of the Report

According to MDS Foundation, myelodysplastic syndrome (MDS) is a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. MDS is often referred to as a “bone marrow failure disorder”. These disorders are characterized by ineffective hematopoiesis, including abnormalities in proliferation, differ­entiation, and apoptosis.

By Treatment Type
Chemotherapy
Immune Treatments
Stem Cell Transplant
Other Treatment Types
By End User
Hospitals
Specialty Clinics
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Stem Cell Transplant Segment Holds a Significant Share in the Market Studied

  • Stem cell transplantation (SCT) offers a potentially beneficial therapy for the patients with myelodysplastic syndromes.
  • There are two major types of SCT, one is allogeneic stem cell transplant and the other is an autologous stem cell transplant.
  • For an allogeneic stem cell transplant, after the bone marrow is destroyed, the patient receives blood-forming stem cells from another person, the donor. This is the type of transplant typically used for MDS.
  • In an autologous stem cell transplant, the patients get back their own stem cells (which were removed before treatment). This type of transplant is not typically used for patients with MDS because the patient's bone marrow contains abnormal stem cells.
MDS Clinical Trials.png

To understand key trends, Download Sample Report

North America dominates the Global Myelodysplastic Syndrome Treatment Market

  • North America dominates the global MDS treatment market owing to the increase in the prevalence of myelodysplastic syndrome, early adoption of novel treatments, high R&D investments on the development of the novel drugs, and the presence of sophisticated healthcare infrastructure.
  • For instance, in December 2019, Bristol-Myers Squibb and Acceleron Pharma announced that the FDA Advisory Committee will review Reblozyl (luspatercept-aamt) for use in patients with myelodysplastic syndrome.
  • Asia-Pacific is expected to experience lucrative growth in the global myelodysplastic syndrome treatment market due to the developing healthcare infrastructure, rapidly improving economic conditions, and a promising regulatory environment for new treatment.
Picture2Myelodysplastic Syndrome.png

To understand geography trends, Download Sample Report

Competitive Landscape

In the market studied, major players are focused on expanding their business in different areas by adopting various market strategies, such as partnerships, collaborations, acquisitions, and mergers. AbbVie, Accord Healthcare, Bristol-Myers Squibb, Celgene Corporation, Takeda Pharmaceutical Company Limited, and Novartis AG are the major market players. 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High R&D Investments on the Development of Novel Treatments for MDS

      2. 4.2.2 Strong Presence of Pipeline Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects Associated with the Medications

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Immune Treatments

      3. 5.1.3 Stem Cell Transplant

      4. 5.1.4 Other Treatment Types

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Specialty Clinics

      3. 5.2.3 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie

      2. 6.1.2 Accord Healthcare

      3. 6.1.3 Bristol-Myers Squibb

      4. 6.1.4 Jazz Pharmaceuticals Inc.

      5. 6.1.5 Novartis

      6. 6.1.6 Lupin

      7. 6.1.7 Otsuka America Pharmaceutical Inc.

      8. 6.1.8 Onconova Therapeutics

      9. 6.1.9 Takeda Pharmaceutical Company Limited

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Myelodysplastic Syndrome (MDS) Treatment Market market is studied from 2018 - 2026.

The Myelodysplastic Syndrome (MDS) Treatment Market is growing at a CAGR of 6.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

  • Otsuka America Pharmaceutical, Inc.
  •  Accord Healthcare
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb
  • LUPIN

Are the major companies operating in Myelodysplastic Syndrome (MDS) Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!